Cargando…

Real‐World Driving Data Indexes Dopaminergic Treatment Effects in Parkinson's Disease

BACKGROUND: Driving is a complex, everyday task that impacts patient agency, safety, mobility, social connections, and quality of life. Digital tools can provide comprehensive real‐world (RW) data on driver behavior in patients with Parkinson's disease (PD), providing critical data on disease s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Jun Ha, Bhatti, Danish, Rizzo, Matthew, Uc, Ergun Y., Bertoni, John, Merickel, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525064/ https://www.ncbi.nlm.nih.gov/pubmed/37772286 http://dx.doi.org/10.1002/mdc3.13803

Ejemplares similares

TURNING REAL-WORLD DATA INTO ACTIONABLE EVIDENCE FOR HEALTHCARE INTERVENTIONS IN NEURODEGENERATION
por: Poulsen, Rachel, et al.
Publicado: (2022)

Driver Speed Profiles Index Warning Signs of MCI
por: Merickel, Jennifer, et al.
Publicado: (2021)

Parkinson’s disease, dopaminergic drugs and the plant world
por: Kempster, Peter, et al.
Publicado: (2022)

Inventory of real world data sources in Parkinson’s disease
por: Tanguy, Audrey, et al.
Publicado: (2017)

Cerebellar Transcranial Direct Current Stimulation in People with Parkinson’s Disease: A Pilot Study
por: Workman, Craig D., et al.
Publicado: (2020)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Resting-state EEG measures cognitive impairment in Parkinson’s disease
por: Anjum, Md Fahim, et al.
Publicado: (2023)

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism
por: Lee, Seung Ha, et al.
Publicado: (2017)

Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease
por: González-Hernández, Tomás, et al.
Publicado: (2010)

Dopaminergic Dysregulation, Artistic Expressiveness, and Parkinson's Disease
por: López-Pousa, S., et al.
Publicado: (2012)

Advances in non-dopaminergic treatments for Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

Dopaminergic modulation of emotional conflict in Parkinson's disease
por: Fleury, Vanessa, et al.
Publicado: (2014)

Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease
por: Buddhala, Chandana, et al.
Publicado: (2015)

Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease
por: Kaasinen, Valtteri
Publicado: (2015)

Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
por: Isaias, Ioannis U., et al.
Publicado: (2016)

Dopaminergic Modulation of Prospective Memory in Parkinson’s Disease
por: Costa, Alberto, et al.
Publicado: (2008)

Dopaminergic modulation of the praxis network in Parkinson's disease
por: Matt, Eva, et al.
Publicado: (2019)

Editorial: Non-Dopaminergic Systems in Parkinson’s Disease
por: Miguelez, Cristina, et al.
Publicado: (2020)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Striatal Dopaminergic Loss and Dysphagia in Parkinson Disease
por: Kim, Ji Hwan, et al.
Publicado: (2023)

Social interactions impact on the dopaminergic system and drive individuality
por: Torquet, N., et al.
Publicado: (2018)

Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson’s Disease
por: Hanganu, Alexandru, et al.
Publicado: (2014)

Roles of FGF20 in dopaminergic neurons and Parkinson's disease
por: Itoh, Nobuyuki, et al.
Publicado: (2013)

Dopaminergic therapy affects learning and impulsivity in Parkinson’s disease
Publicado: (2014)

Parkinson’s disease: animal models and dopaminergic cell vulnerability
por: Blesa, Javier, et al.
Publicado: (2014)

Dopaminergic modulation of motor network dynamics in Parkinson’s disease
por: Michely, Jochen, et al.
Publicado: (2015)

Dopaminergic therapy affects learning and impulsivity in Parkinson’s disease
por: Hiebert, Nole M, et al.
Publicado: (2014)

Asymmetric Dopaminergic Degeneration and Attentional Resources in Parkinson’s Disease
por: Ortelli, Paola, et al.
Publicado: (2018)

Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease
por: Mao, Qi, et al.
Publicado: (2020)

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies
por: Gomez-Inhiesto, Elisa, et al.
Publicado: (2020)

Investigating Established EEG Parameter During Real-World Driving
por: Protzak, Janna, et al.
Publicado: (2018)

Endogenous fluctuations in the dopaminergic midbrain drive behavioral choice variability
por: Chew, Benjamin, et al.
Publicado: (2019)

Multimodal Data Collection System for Driver Emotion Recognition Based on Self-Reporting in Real-World Driving
por: Oh, Geesung, et al.
Publicado: (2022)

Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
por: Dujardin, Kathy, et al.
Publicado: (2020)

World Health Organization
por: Ogbu, U.C., et al.
Publicado: (2008)

Editorial: Real-world data and real-world evidence in hematologic malignancies
por: Malagola, Michele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9r8v40jtrteepq4sj0otvsja6g